ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of t
George Canellos
ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of the Dana-Farber Cancer Institute in Boston — who gives eCancerRadio his opinion of two papers presented at the American Society of Hematology annual meeting (December 3-7, 2010) held in Orlando: one from California comparing the two regimens in patients with stage I/II bulky mediastinal Hodgkin Lymphoma; the second from Illinois in which the same comparison was made in patients who had locally extensive and advanced stage disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/101210GeorgeCanellos415n6PODCASTLoRes.mp3]
Related Episodes
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
María-Victoria Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.